Indivior Pharmaceuticals
INDV
60 hedge funds and large institutions have $1.86B invested in Indivior Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 60 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
44.95% more ownership
Funds ownership: 0% → 44.95% (+45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$313M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$220M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$132M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.1M |
| 5 |
Goldman Sachs
New York
|
+$80.6M |
Top Sellers
INDV Hedge Fund Activity: Q2 2023 in Review
60 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q2 2023, worth a combined $1.86B.
Buyers outnumbered sellers: 60 funds opened new INDV positions and 0 closed out — a net gain of 60 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Two Seas Capital, opening a new position worth an estimated $313M.
- 60 institutional investors held Indivior Pharmaceuticals (INDV) as of Q2 2023, up from 0 in Q1 2023.
- Funds reported $1.86B of Indivior Pharmaceuticals stock for Q2 2023.
- 60 funds opened new Indivior Pharmaceuticals positions in Q2 2023 and 0 closed out, a net change of +60 holders.
- The largest Indivior Pharmaceuticals buyer in Q2 2023 was Two Seas Capital, an estimated $313M added.
Based on aggregated 13F filings for Q2 2023.